
Christopher Kramer MD
@chriskramermd
Chief, CV Division and George Beller Professor, UVA. CV Imager. VP, ACC. Husband, proud dad of an actor/PAC director and a sales specialist. Tweets my own.
ID: 4844807429
25-01-2016 08:50:15
1,1K Tweet
3,3K Followers
1,1K Following


SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening #heartfailure events & improved #QoL in patients w/ #HFpEF & obesity. “Cardiologists now have an ever-expanding armamentarium to treat HFpEF,” says Dr. Christopher Kramer MD. bit.ly/4hSxZ9J


ACC@75 here in Chicago supporting our partner and celebrating AHA@100. We are stronger together with Guidelines and Science B. Hadley Wilson MD Cathie Biga Christopher Kramer MD Minnow Walsh, MD, MACC American College of Cardiology Atrium Health #AHA2024 WilliamZoghbi


Drs Renée Bullock-Palmer MD FACC FAHA FASNC FASE FSCCT and Christopher Kramer MD share the new #CVBoard of Medicine’s vision for evaluating clinical expertise, demonstrating continuous clinical and professional competence and ultimately providing value to clinicians and patients. Learn more about the Board at


Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) nej.md/4hRGaTY #AHA24 | AHA Science


Started today with great panel ACC-AHA Session on the new American Board of Cardiovascular Medicine for better care of our patients.Hope to have approval soon. B. Hadley Wilson MD Cathie Biga Christopher Kramer MD American College of Cardiology Atrium Health David Allen Faxon Jeff Kuvin


#AHA24: In the #CMR substudy of the #SUMMIT trial, Dr. Christopher Kramer MD & team in #JACC show that tirzepatide decreased LV mass and paracardiac adipose tissue - a potential mechanism for reduced #heartfailure events bit.ly/3CytSPZ #Obesity


Christopher Kramer MD #AHA24 #SUMMIT #WhyCMR substudy on BNP deficiency subset of HFpEF 106 pts (Tirzepatide 50 🆚 placebo 56) mostly in 🇦🇷 🇧🇷 Finds ⬇️LV mass(11 Gm) linear to weight loss ⬇️ adipose tissue pericardial not epicardial bit.ly/4hXoCpd



5/ Key takeaway: Tirzepatide offers a novel approach to reduce cardiac stress and adiposity in obesity-related HFpEF - and it improves outcomes. Substudy led by Christopher Kramer MD. JACC Journals Read the full study: jacc.org/doi/10.1016/j.…

#AHA24 ICYMI: #JACC AE Dr. Neha Pagidipati, Neha Pagidipati, & lead author Dr. Christopher Kramer MD discuss the results of the #CMR substudy of the #SUMMIT trial 📄: bit.ly/3CytSPZ

Check out this fantastic infographic by Sahi Allam, MD summarizing key points from SEQUOIA-HCM below ⤵️ and remember to join us tonight on X at 8PM for a live discussion with experts! Follow along with #CardsJC for the discussion!



news.med.virginia.edu/research/new-t… New Technique Better Diagnoses Deadly Coronary Artery Disease UVA Cardio UVA Cardiology Fellowship Christopher Kramer MD #UVAMedicine #UVADoM #UVADeptOfMedicine

cbs19news.com/news/researche… UVA Health researcher Dr. Christopher Kramer explains how a weight-loss drug can reduce the risk of death from heart failure. UVA Cardio UVA Cardiology Fellowship Christopher Kramer MD #UVACardio #UVAMedicine #UVADoM #UVADeptOfMedicine

Excited to announce that James McNamara MD of UTSW, former UVA School of Medicine student, will be joining UVA Cardio in June '25 as Assoc. Director of the Echo Lab and member of the HCM COE. Welcome home James! UVA Cardiology Fellowship Jamieson Bourque JLindnerMD Amit R. Patel mike valentine MD MACC,FSCAI,FAHA


ACC Advocacy American College of Cardiology So honored to be a part of the official signing of this bill, which has been a key priority of American College of Cardiology and our members. #ACCAdvocacy @cardiology
